Leerink analyst Roanna Ruiz raised the firm’s price target on Cytokinetics (CYTK) to $83 from $73 and keeps an Outperform rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $95 from $87 at RBC Capital
- Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating
- Cytokinetics price target raised to $99 from $95 at Goldman Sachs
- Cytokinetics price target raised to $88 from $78 at Citizens
- Cytokinetics price target raised to $136 from $120 at H.C. Wainwright